Innovative Drug Development in Dermatology
Latest News

February 3, 2015

Brickell Announces $10M Series C Financing.

Initiates Phase 2b Study of BBI-4000 in Patients with Axillary Hyperhidrosis.

Acquires Novel, Clinical-Stage Compound for the Oral Treatment of Atopic Dermatitis.

Read Article (PDF)

Focused on the development of novel therapies for the treatment of skin diseases.

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative, first-in-class therapeutics to satisfy current unmet human needs in the global dermatology markets.



Brickell Biotech, Inc. © 2015 All Rights Reserved.